Ignite Creation Date:
2024-05-06 @ 6:25 PM
Last Modification Date:
2024-10-26 @ 2:48 PM
Study NCT ID:
NCT05659056
Status:
RECRUITING
Last Update Posted:
2024-04-16
First Post:
2022-12-02
Brief Title:
Neoadjuvant Study With Pyrotinib and Trastuzumab and Abraxane in Patients With HER2-enriched Breast Cancer
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
The First Affiliated Hospital with Nanjing Medical University
Study Overview
Official Title:
Neoadjuvant Treatment of Pyrotinib in Combination With Trastuzumab and Abraxane in Patients With HER2-enriched Early or Locally Advanced Breast Cancer a Single One Arm Multicenter II Phase Study
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Breast cancer is kind of highly heterogeneous tumor The patients with the same stage and with the same treatment regimen their prognosis varies greatly mainly due to the different phenotypes of breast cancer and different sensitivities to drug therapy PMA50 and BluePrint classification divides breast cancer into other inherent subtypes Luminal A Luminal B HER2-enriched HER2-E and Basal-like Previous studies have shown that these patients with inherent subtype of HER2-enriched are more likely to obtain higher pCR after anti-HER2 therapy And more study and meta analysis had demonstrated the higher pCR is closely related to EFS The genetic and molecular typing of breast cancer is closely related to the prognosis of breast cancer so it is imperative to seek a new treatment regimen for precision treatment and maximize the therapeutic benefit of HER2-enriched patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None